Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Other Accumulated Expenses (2016 - 2025)

IGC Pharma has reported Other Accumulated Expenses over the past 12 years, most recently at $146000.0 for Q3 2025.

  • Quarterly Other Accumulated Expenses rose 102.78% to $146000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $146000.0 through Sep 2025, up 102.78% year-over-year, with the annual reading at $1.0 million for FY2025, 382.21% up from the prior year.
  • Other Accumulated Expenses was $146000.0 for Q3 2025 at IGC Pharma, down from $401000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $1.0 million in Q1 2025 and troughed at $72000.0 in Q3 2024.
  • The 3-year median for Other Accumulated Expenses is $209000.0 (2023), against an average of $363333.3.
  • Year-over-year, Other Accumulated Expenses tumbled 41.9% in 2024 and then surged 382.21% in 2025.
  • A 3-year view of Other Accumulated Expenses shows it stood at $209000.0 in 2023, then skyrocketed by 243.06% to $717000.0 in 2024, then tumbled by 79.64% to $146000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Other Accumulated Expenses are $146000.0 (Q3 2025), $401000.0 (Q2 2025), and $1.0 million (Q1 2025).